We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Adaptate Biotherapeutics Formed To Develop T-cell Modulating Antibody-based Therapies

Adaptate Biotherapeutics Formed To Develop T-cell Modulating Antibody-based Therapies  content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GammaDelta Therapeutics, a company focused on harnessing the unique properties of gamma delta (γd) T-cells to develop transformational immunotherapies, has announced the formation of a spin-out company: Adaptate Biotherapeutics. While GammaDelta Therapeutics’ primary goal is to develop γd T-cell based cell therapy products, the new spin-out will build on GammaDelta’s knowledge to modulate γd T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.

γd T-cells are a distinct T-cell sub-type that respond to molecular patterns of distress and have been shown to have tremendous potential in treating cancer and other immunological disorders. GammaDelta Therapeutics was formed in 2016 to harness these properties, and since then has gained knowledge of γd T-cell biology developing a portfolio of investigational cell therapies poised to enter clinical development. In addition to gaining insight into cell growth and isolation, the company’s scientists have also discovered a number of potential drug targets and antibodies that have potential to modulate the activity of γd T-cells in situ.

Adaptate Biotherapeutics has been formed to further develop these targets and antibodies for therapeutic purposes and advance them into clinical studies. The two companies will continue sharing their insights into γd T-cell biology as they work towards developing different therapeutic modalities.